Full-Time

Director – Clinical Operations

Posted on 8/23/2024

Tango Therapeutics

Tango Therapeutics

51-200 employees

Develops targeted cancer therapies using synthetic lethality

Biotechnology
Healthcare

Senior

Boston, MA, USA

Office located at 201 Brookline Avenue, in the Fenway area of Boston, Massachusetts.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Google Cloud Platform
PowerPoint/Keynote/Slides
Requirements
  • BA/BS preferably in nursing, biology, biochemistry or related area (advanced degree desired), with at least 12 years of experience in clinical research operations
  • Minimum of 2 years of oncology experience required, 5+ years preferred
  • Biotechnology experience required
  • Early phase experience, including IND submissions, required
  • Strong vendor management and project management skills are critical
  • Excellent written and oral communication skills
  • Strong working knowledge of GCP/ICH and other applicable regulations/guidelines, required
  • Good organizational/prioritization skills with strong attention to detail
  • Working knowledge of oversight requirements and an eye for quality, required
  • Strong proficiency with MS Office programs such as Outlook, Word, Excel, PowerPoint, and SharePoint, required
  • Collaborative spirit for working positively and effectively with cross-functional teams and partners is essential
  • Travel of up to 25% required
Responsibilities
  • You will oversee the development of clinical trial project timelines and ensure communication and understanding of risks and challenges; establish plans and monitor metrics; ensure that timelines are accurate and comprehensive
  • Work cross-functionally to coordinate the relevant and timely exchange of information and materials to support clinical trial deliverables
  • Manage clinical trials from start-up through close-out to ensure that both internal and external deliverables are on time and on budget while collaborating across functional areas
  • Proactively manage clinical trial outsourced partners, including identification of risk, to ensure trial deliverables and performance goals are met
  • Maintain partnerships and positive and productive relationships with CRO counterparts; proactively review and identify potential issues or problems with the sites and communicate/escalate to clinical leadership
  • Collaborate with CROs to keep the clinical study database current, accurate, and routinely cleaned
  • Manage the scope of work, change notifications, contract modification, site trial agreements, and other necessary budgetary information for clinical trial operations
  • Support and manage oversight activities of all necessary vendors to ensure a high level of operational excellence is maintained
  • Additional duties and responsibilities as required

Tango Therapeutics develops targeted cancer treatments using the principle of synthetic lethality, which allows them to design drugs that kill cancer cells while leaving healthy cells unharmed. Their approach focuses on the interaction between genes, where the loss of both genes leads to cell death, but the loss of just one does not. This method enables them to create therapies that are more precise in targeting tumors. Tango operates in the oncology market, primarily serving healthcare providers and pharmaceutical companies interested in advanced cancer therapies. They collaborate with larger pharmaceutical firms, like Gilead Sciences, to co-develop these treatments, which helps them secure funding and speed up the development process. Tango's goal is to bring next-generation targeted immunotherapies to market, supported by a strong team and strategic partnerships.

Company Stage

IPO

Total Funding

$341.4M

Headquarters

Cambridge, Massachusetts

Founded

2017

Growth & Insights
Headcount

6 month growth

2%

1 year growth

17%

2 year growth

87%
Simplify Jobs

Simplify's Take

What believers are saying

  • FDA's Fast Track designation for TNG462 suggests a favorable regulatory environment.
  • Growing interest in synthetic lethality boosts Tango's market potential.
  • Increasing prevalence of MTAP-deleted tumors presents a significant market opportunity.

What critics are saying

  • Discontinuation of TNG348 due to liver toxicity may impact investor confidence.
  • Reliance on partnerships for financial support poses a risk if altered or terminated.
  • Intensifying competition in precision oncology could affect Tango's market share.

What makes Tango Therapeutics unique

  • Tango leverages synthetic lethality to target cancer cells while sparing healthy ones.
  • Their focus on tumor suppressor gene loss is a novel approach in oncology.
  • Collaboration with Gilead Sciences accelerates development and commercialization of therapies.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE